Natalie Gukasyan, MD
@N_Gukasyan
Followers
3K
Following
861
Statuses
445
Psychiatrist | Researcher @ColumbiaPsych. Former medical director @JHPsychedelics. Exploring clinical applications of psychedelics
New York, NY
Joined December 2017
Our new survey study of hallucinogen persisting perception disorder (HPPD) experiences is now open. We hope this will help us glean new insights about phenomenology, risk factors, and treatment options for this condition. Please share/RT!
20
61
84
RT @ExistWell: We analyzed 2 decades of materials used in psilocybin trials. We examined how “set and setting” is communicated to participa…
0
16
0
How are psychiatric training programs incorporating training about psychedelics? Led by Bit Yaden @JHPsychedelics w/ colleagues at NYU and Yale, our recent article surveying psychiatric residency program directors takes a snapshot
2
2
30
RT @ExistWell: New article: Quantitative summary of adverse events in psychedelic studies. We find a favorable safety profile, but with ma…
0
24
0
RT @RCarhartHarris: Enjoying this paper on mechanistic factors contributing to psilocybin-therapy for depression. Insight comes screaming t��
0
17
0
@trpwolff @Titoschmi @ManojDoss @JacobSAday @RickZeifman @Drug_Researcher @FredBarrettPhD @RCarhartHarris @KatrinPreller @PLiknaitzky @LeorRoseman maybe a heightened sense of novelty or salience
0
0
9
And 4) general changes in the adcom system in which there would no longer be a vote but rather the adcom would be asked to advise FDA. This seemed a bit murky since voting has already occurred. 4/4
1
0
12
Torsten Passie at #ICPR2024 presents this quote from Humphry Osmond on whether therapists should have their own experience with psychedelics:
2
3
30
@FredBarrettPhD I thought it was more of a concern for the safety data. Could look safer then it actually is if you have experienced participants who know what to expect and have done it before without significant side effects
2
0
4
Interesting that there was no mention of the therapy portion of the intervention in this question. But I guess it's understandable given that it is the FDA and not the FDPA (Food, Drug, and Psychotherapy Administration). Some referenced the therapy in their answers though.
BREAKING: In 9-2 Vote, AdComm Finds Available Data Insufficient to Show MDMA-AT Effective in PTSD Verbatim question: Do the available data show that the drug is effective in patients with posttraumatic stress disorder? 2 Yes / 9 No
2
1
7
@JasterAlaina Ahh ok, I've been floating in and out today so missed this. Do you know what they suggested specifically? From what I know about some of the psilocybin phase III study designs it seems like they'd be hit with the same critiques.
3
0
0
Seems like a good time to plug my talk at ICPR – "The (new) great psychotherapy debate: the role of adjunctive therapy in psychedelic interventions and implications for long-term outcomes"
3
4
38
RT @ExistWell: New @NIH_NCCIH study launching: Psilocybin and Affective Function in Chronic Low Back Pain and Depression (CLBP+D). Me & @p_…
0
28
0
RT @WilliamStoops: Truly a joy to write this paper with some stellar friends and colleagues! @ceciliabergeria @juststrickland @CassieGipson…
0
7
0